Business Description
Northwest Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US66737P6007
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | -2.36 | |||||
Debt-to-Equity | -0.69 | |||||
Debt-to-EBITDA | -0.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -73.07 | |||||
Beneish M-Score | -3.32 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 58.9 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 1.3 | |||||
3-Year Book Growth Rate | 49.6 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.09 | |||||
Quick Ratio | 0.09 | |||||
Cash Ratio | 0.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 | |||||
Shareholder Yield % | -1 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2873.09 | |||||
Net Margin % | -3240.11 | |||||
FCF Margin % | -2928.39 | |||||
ROA % | -205.93 | |||||
ROIC % | -93.23 | |||||
ROC (Joel Greenblatt) % | -274.5 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 488 | |||||
EV-to-EBIT | -10.93 | |||||
EV-to-EBITDA | -11.27 | |||||
EV-to-Revenue | 324.41 | |||||
EV-to-FCF | -10.98 | |||||
Earnings Yield (Greenblatt) % | -9.15 | |||||
FCF Yield % | -9.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Northwest Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 1.564 | ||
EPS (TTM) (£) | -0.048 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (£) | 0 | ||
20-Day SMA (£) | 2.4 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (£) | 2.4 - 2.4 | ||
Shares Outstanding (Mil) | 1,195.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Northwest Biotherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Northwest Biotherapeutics Inc Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Northwest Biotherapeutics Inc Frequently Asked Questions
What is Northwest Biotherapeutics Inc(LTS:0K95)'s stock price today?
When is next earnings date of Northwest Biotherapeutics Inc(LTS:0K95)?
Does Northwest Biotherapeutics Inc(LTS:0K95) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |